PTO/SB/08a (08-03)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10680076	
	Filing Date		2003-10-06	
INFORMATION DISCLOSURE	First Named Inventor Thor		omas Bell	
(Not for submission under 37 CFR 1.99)	Art Unit		1624	
	Examiner Name	COLEMAN, Brenda Libby		
	Attorney Docket Number		36-02	

					U.S.F	PATENTS					
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Da	ate	Name of Pate of cited Docu	of Patentee of Applicant   Doloront Do			Passages or Relevant	
	1										
If you wisl	n to ac	dd additional U.S. Pate	nt citatio	n informa	tion pl	ease click the	Add button.	<u> </u>			
			U.S.P	ATENT A	APPLIC	CATION PUBI	LICATIONS				
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publicat Date	ion	Name of Patentee or Applican of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1										
If you wisl	n to ac	dd additional U.S. Publ	ished Ap	plication	citation	n information p	please click the Ado	buttor	٦.		
			·	FOREIG	N PAT	ENT DOCUM	ENTS			,	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code4	Publication Date	Name of Patented Applicant of cited Document			<b>T</b> 5	
	1					·					
If you wisl	n to ac	। dd additional Foreign P	atent Do	cument c	itation	information pl	ease click the Add	button		L	
		<u></u>	NON	I-PATEN	T LITE	RATURE DO	CUMENTS				
Examiner Initials*	Cite No	Include name of the a (book, magazine, jour publisher, city and/or	rnal, seria	al, sympo	sium,	catalog, etc), o				<b>T</b> 5	

## Application Number 10680076 Filing Date 2003-10-06 INFORMATION DISCLOSURE First Named Inventor Thomas Bell STATEMENT BY APPLICANT Art Unit 1624 ( Not for submission under 37 CFR 1.99) Examiner Name COLEMAN, Brenda Libby Attorney Docket Number 36-02 BELL, T.W., et al., Synthesis and Structure - Activity Relationship Studies of CD4 Down-Modulating Cyclotriazadisulfonamide (DADA) Analogues, J. Med. Chem. 2006, 49, 1291-1312. Published on Web 02/02/2006. 1 If you wish to add additional non-patent literature document citation information please click the Add button **EXAMINER SIGNATURE** Examiner Signature **Date Considered** \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if

English language translation is attached.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10680076		
Filing Date		2003-10-06		
First Named Inventor	Thom	mas Beli		
Art Unit		1624		
Examiner Name	COL	EMAN, Brenda Libby		
Attorney Docket Number		36-02		

CERTIFICATION STATEMENT								
Ple	Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):							
	That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).							
OF	OR							
	That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).							
	See attached certification statement.							
	Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.							
×	None     Non							
SIGNATURE  A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.								
Sig	nature	Sally & Bullin	Date (YYYY-MM-DD)	2006-07-27				
Name/Print SALLY A. SULLIVÁN		Registration Number	32064					
	This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR							

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**